All these roads are pointing in one direction, that COVID-19 increases the risk of diabetes up to a year later. If patients have a prior history of COVID-19.they should certainly be screened for diabetes.
In low- to middle-income countries, SGLT2 inhibitors could reduce diabetes complications at lower but feasible prices; they are cost effective at current prices in people with heart or kidney disease.
The drugs were linked to improvements in Graves orbitopathy, even in people without high LDL-cholesterol; anti-inflammatory effects a possible explanation.
(0) TEPEZZA significantly improved the clinical course of Thyroid Eye Disease (TED) in all patient subgroups, including those with more severe disease at baseline For patients in the follow-up period with data available at 51 weeks after the last dose of TEPEZZA, 67 percent had a proptosis response, 69 percent had a diplopia response and 83 percent had an ophthalmic composite outcome response
Horizon Therapeutics plc (Nasdaq: HZNP) today announced that new pooled data from the TEPEZZA (teprotumumab-trbw) Phase 2 and Phase 3 clinical trials are now published in
The
Lancet Diabetes Endocrinology. The data further reinforce that TEPEZZA significantly improves proptosis (eye bulging) and diplopia (double vision) for TED patients in different subgroups, with most maintaining a long-term response. TEPEZZA the first and only medicine approved by the U.S. Food and Drug Administration (FDA) for TED is a fully human monoclonal antibody (mAb) and a targeted inhibitor of the insu